Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Retatrutide's triple-agonist mechanism produced the highest weight loss of any anti-obesity agent in clinical trials (28.7% at 68 weeks in Phase 3 TRIUMPH-4), confirming that the addition of GIP receptor agonism to the GLP-1/glucagon backbone provides substantial incremental benefit
This preserves muscle mass during rapid weight loss
What should you eat while taking semaglutide
2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user
That dynamic shifted in 2024, when Wegovy gained an indication for reduced cardiovascular risk in March and Zepbound added an OSA indication in December
US$ 26.51
US$ 21.32
US$ 20.61
US$ 26.88
US$ 23.47
US$ 20.89
